A J van Sorge1, J U M Termote2, H J Simonsz3, F T Kerkhoff4, L J van Rijn5, W A J G Lemmens6, N E Schalij-Delfos1. 1. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. 2. Department of Neonatology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Ophthalmology, Children's Hospital Erasmus MC-Sophia, Rotterdam, Southern Holland, The Netherlands. 4. Department of Ophthalmology, Maxima Medical Center, Veldhoven, Limburg, The Netherlands. 5. Department of Ophthalmology, VU University Medical Center, Amsterdam, North-Holland, The Netherlands. 6. Department for Health Evidence, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Abstract
PURPOSE: Provide insight in natural history, screening and treatment policy of retinopathy of prematurity (ROP) in The Netherlands. METHODS: A multicentre, prospective, population-based study (NEDROP) included all preterm infants born in 2009 in The Netherlands fulfilling the inclusion criteria for ROP screening. Anonymised data from ophthalmologists, neonatologists and paediatricians were merged on identification number. RESULTS: Of 2033 reported infants, 1688 (83%) were screened for ROP. ROP stage was reported in 100%, zone in 94.4% and plus disease in 83%. ROP developed in 324 (19.2%), mild ROP (stage 1-2) in 294 (17.4%), severe ROP (stage 3 or more) in 30 (1.8%) and 17 (1%) were treated. The initial screening examination was not performed within the required 42 days in 641 (38%). Date for follow-up was recorded 1973 times and accomplished within 3 days from the planned date in 1957 (99.2%). The chance of not being screened increased from 12.9% without transfer to another hospital to 23.5, 18.5 and 25% after 1, 2, or 3 transfers, respectively. CONCLUSIONS: The incidence of severe ROP and infants treated was low. NEDROP emphasises that timing of initial examination and transfer to another hospital are issues of concern within the screening process. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
PURPOSE: Provide insight in natural history, screening and treatment policy of retinopathy of prematurity (ROP) in The Netherlands. METHODS: A multicentre, prospective, population-based study (NEDROP) included all preterm infants born in 2009 in The Netherlands fulfilling the inclusion criteria for ROP screening. Anonymised data from ophthalmologists, neonatologists and paediatricians were merged on identification number. RESULTS: Of 2033 reported infants, 1688 (83%) were screened for ROP. ROP stage was reported in 100%, zone in 94.4% and plus disease in 83%. ROP developed in 324 (19.2%), mild ROP (stage 1-2) in 294 (17.4%), severe ROP (stage 3 or more) in 30 (1.8%) and 17 (1%) were treated. The initial screening examination was not performed within the required 42 days in 641 (38%). Date for follow-up was recorded 1973 times and accomplished within 3 days from the planned date in 1957 (99.2%). The chance of not being screened increased from 12.9% without transfer to another hospital to 23.5, 18.5 and 25% after 1, 2, or 3 transfers, respectively. CONCLUSIONS: The incidence of severe ROP and infants treated was low. NEDROP emphasises that timing of initial examination and transfer to another hospital are issues of concern within the screening process. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Child health (paediatrics); Epidemiology; Retina
Authors: Femke J Drost; Kristin Keunen; Pim Moeskops; Nathalie H P Claessens; Femke van Kalken; Ivana Išgum; Elsbeth S M Voskuil-Kerkhof; Floris Groenendaal; Linda S de Vries; Manon J N L Benders; Jacqueline U M Termote Journal: Pediatr Res Date: 2018-02-07 Impact factor: 3.756
Authors: Kasia Trzcionkowska; Wouter B H J Vehmeijer; Frank T Kerkhoff; Noel J C Bauer; Carlien A M Bennebroek; Peter H Dijk; Koen P Dijkman; Frank A M van den Dungen; Cathrien A Eggink; Robert P G Feenstra; Floris Groenendaal; Arno F van Heijst; Mark A H B M van der Hoeven; Rene F Kornelisse; Elke Kraal-Biezen; Enrico Lopriore; Wes Onland; Victor W Renardel de Lavalette; Laurentius J van Rijn; Frank A B A Schuerman; Huibert J Simonsz; Elsbeth S M Voskuil-Kerkhof; Ruben S G M Witlox; Jacqueline U M Termote; Nicoline E Schalij-Delfos Journal: Acta Ophthalmol Date: 2020-07-23 Impact factor: 3.761